Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant.

ABSTRACT:

Background

Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine. Secondary aims included the determination of factors predicting breakthrough infection.

Methods

COVID-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4-10 weeks following first and second vaccine doses in cirrhosis [n = 325; 94% messenger RNA (mRNA) and 6% viral vaccine], autoimmune liver

SUBMITTER: Mehta G 

PROVIDER: S-EPMC10586829 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature